Glutamate release inhibition ineffective in levodopa-induced motor complications

被引：24

作者：

Bara-Jimenez, William ^{[1
]}

Dimitrova, Tzvetelina D. ^{[1
]}

Sherzai, Abdullah ^{[1
]}

Aksu, Murat ^{[1
]}

Chase, Thomas N. ^{[1
]}

机构：

[1] NINDS, Expt Therapeut Branch, NIH, Bethesda, MD 20892 USA

来源：

MOVEMENT DISORDERS | 2006年 / 21卷 / 09期

关键词：

glutamate; riluzole; dopamine; Parkinson's disease; dyskinesias; levodopa; striatum;

D O I：

10.1002/mds.20976

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Reported benefits of various glutamatergic receptor antagonists in Parkinson's disease (PD) prompted an evaluation of the antidyskinetic effect of a putative glutamate release inhibitor in 15 moderately advanced patients. In a 3-week, double-blind, proof-of-concept study, riluzole (200 mg/day) failed to alter parkinsonian or levodopa-induced motor complication severity. Opposing effects of a generalized inhibition of glutamate-mediated synaptic transmission may limit the usefulness of this approach to treat PD. (c) 2006 Movement Disorder Society.

引用

页码：1380 / 1383

页数：4

共 22 条

[1] Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease [J].

Bara-Jimenez, W ;

Dimitrova, T ;

Sherzai, A ;

Favit, A ;

Mouradian, MM ;

Chase, TN .

MOVEMENT DISORDERS, 2004, 19 (10) :1183-1186

[2] Adenosine A2A receptor antagonist treatment of Parkinson's disease [J].

Bara-Jimenez, W ;

Sherzai, A ;

Dimitrova, T ;

Favit, A ;

Bibbiani, F ;

Gillespie, M ;

Morris, MJ ;

Mouradian, MM ;

Chase, TN .

NEUROLOGY, 2003, 61 (03) :293-296

[3] Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model [J].

Bezard, E ;

Stutzmann, JM ;

Imbert, C ;

Boraud, T ;

Boireau, A ;

Gross, CE .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 356 (2-3) :101-104

[4] Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms [J].

Blanchet, PJ ;

Calon, F ;

Morissette, M ;

Tahar, AH ;

Bélanger, N ;

Samadi, P ;

Grondin, R ;

Grégoire, L ;

Meltzer, L ;

Di Paolo, T ;

Bédard, PJ .

PARKINSONISM & RELATED DISORDERS, 2004, 10 (05) :297-304

[5] Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey [J].

Boraud, T ;

Bezard, E ;

Stutzmann, JM ;

Bioulac, B ;

Gross, CE .

NEUROSCIENCE LETTERS, 2000, 281 (2-3) :75-78

[6] Effect of riluzole on dyskinesia and duration of the ON state in Parkinson disease patients - A double-blind placebo-controlled pilot study [J].

Braz, CA ;

Borges, V ;

Ferraz, HB .

CLINICAL NEUROPHARMACOLOGY, 2004, 27 (01) :25-29

[7] Levodopa-induced dyskinesia in Parkinson's disease [J].

Brotchie, JM ;

Lee, J ;

Venderova, K .

JOURNAL OF NEURAL TRANSMISSION, 2005, 112 (03) :359-391

[8] Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons [J].

Centonze, D ;

Calabresi, P ;

Pisani, A ;

Marinelli, S ;

Marfia, GA ;

Bernardi, G .

NEUROPHARMACOLOGY, 1998, 37 (08) :1063-1070

[9] Striatal plasticity and extrapyramidal motor dysfunction [J].

Chase, TN .

PARKINSONISM & RELATED DISORDERS, 2004, 10 (05) :305-313

[10] Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats [J].

Gilgun-Sherki, Y ;

Melamed, E ;

Ziv, I ;

Offen, D .

PHARMACOLOGY & TOXICOLOGY, 2003, 93 (01) :54-56

← 1 2 3 →